P420 Comparative efficacy and safety of oral ferric maltol in Inflammatory Bowel Disease patients with mild-to-moderate vs. more severe iron deficiency anaemia
Akriche, F.(1);Jacob, I.(2);Schmidt, C.(3);Howaldt, S.(4);
(1)Norgine, Medical, Uxbridge, United Kingdom;(2)Health Economics and Outcomes Research Ltd, Health Economics, Cardiff, United Kingdom;(3)Medical Clinic II- Fulda Hospital, Campus Fulda of Marburg University Hospital, Fulda, Germany;(4)HaFCED e.K., Hamburg Institute of IBD Research, Hamburg, Germany
Background
The efficacy and safety of ferric maltol (FM) has been demonstrated in inflammatory bowel disease (IBD) patients with mild-to-moderate iron deficiency anaemia (IDA; haemoglobin [Hb] ≥ 9.5 g/dL). New data are available from a recent open-label, Phase 3b non-inferiority study comparing the efficacy and safety of FM to ferric carboxymaltose for IBD patients with more severe IDA (Hb at screening: 8.0 - 11.0/12.0 g/dL [women/men]) (NCT02680756). Though the primary endpoint was not met, this post hoc analysis aimed to utilise patient-level data to confirm the efficacy and safety of FM in patients with baseline Hb < 9.5 g/dL.
Methods
Patients assigned to FM (N=125) were grouped based on baseline Hb: <9.5 g/dL (n=38) and ≥9.5 g/dL (n=87). Univariate and multivariate analyses were performed for primary (Week 12 change from baseline [CFB] Hb) and key secondary endpoints (Week 12 responder rate [≥2 g/dL Hb increase or Hb normalisation] and long-term efficacy). Safety analysis was performed.
Results
Overall, demographic characteristics were broadly comparable with a greater, but not significant, proportion of females (63.2% vs. 50.6%), women of childbearing age (75.0% vs. 63.6%) and active Crohn’s disease (37.5% vs. 32.7%) in patients with baseline Hb < 9.5 g/dL vs. ≥ 9.5 g/dL, respectively. Mean baseline Hb was 8.6 g/dL in patients with baseline Hb < 9.5 g/dL and 10.6 g/dL in patients with baseline Hb ≥ 9.5 g/dL. There was no significant difference in mean CFB Hb at Week 12 (2.92 g/dL vs. 2.35 g/dL, p=0.960) and Week 12 responder rates (70.0% vs. 67.1%, p=0.523) in patients with baseline Hb < 9.5 g/dL and ≥ 9.5 g/dL, respectively. Mean CFB Hb was numerically but not significantly higher in patients with baseline Hb < 9.5 g/dL at every visit up to Week 52 (Table 1). Drug-related treatment emergent adverse events were similar between < 9.5 g/dL and ≥ 9.5 g/dL Hb groups (15.8% vs. 21.3%, respectively); all non-serious.
Table 1. Observed outcomes (intention-to-treat population):
| Hb < 9.5 g/dL (N=38) | Hb ≥ 9.5 g/dL (N=87) | p-value | |
| Responder*, n (%) | |||
| Week 12 | 21 (70.0) | 51 (67.10) | 0.523 |
| Change from baseline Hb (g/dL), mean (SD) | |||
| Week 12 | 2.92 (1.52) | 2.35 (1.40) | 0.960 |
| Week 24 | 3.53 (1.77) | 2.64 (1.72) | 0.981 |
| Week 36 | 3.93 (2.27) | 2.82 (1.86) | 0.956 |
| Week 52 | 4.27 (2.00) | 2.70 (1.82) | 0.986 |
| *≥2 g/dL increase or Hb normalisation | |||
Conclusion
FM achieved consistent and clinically meaningful increases in Hb in patients with baseline Hb < 9.5 g/dL that were comparable to patients with Hb ≥ 9.5 g/dL. No safety differences were identified between both groups. These data suggest that FM is effective and well tolerated in IBD patients with IDA regardless of baseline Hb.